MeSH term
Frequency | Condition_Probility | Humans | 712 | 0.0 |
Female | 156 | 0.0 |
Middle Aged | 49 | 0.0 |
Adolescent | 69 | 0.0 |
Adult | 109 | 0.0 |
Child | 70 | 0.0 |
Child, Preschool | 46 | 0.0 |
Cystic Fibrosis Transmembrane Conductance Regulator/*genetics | 139 | 92.0 |
Forced Expiratory Volume | 4 | 4.0 |
Genotype | 74 | 0.0 |
Infant | 38 | 0.0 |
Animals | 209 | 0.0 |
Cystic Fibrosis/metabolism/*therapy | 3 | 75.0 |
Cystic Fibrosis Transmembrane Conductance Regulator/genetics/metabolism | 8 | 57.0 |
Gene Expression | 39 | 0.0 |
Gene Therapy/*methods | 9 | 2.0 |
Genetic Vectors/*administration & dosage/genetics | 3 | 18.0 |
Lentivirus/*genetics | 3 | 7.0 |
Research Support, Non-U.S. Gov't | 547 | 0.0 |
Respiratory Mucosa/*metabolism | 3 | 21.0 |
ATP-Binding Cassette Transporters/metabolism | 3 | 6.0 |
Alleles | 37 | 0.0 |
Amino Acid Motifs | 7 | 0.0 |
Amino Acid Sequence | 50 | 0.0 |
Blotting, Western | 20 | 0.0 |
Cell Line | 93 | 0.0 |
Cyclic AMP/metabolism | 19 | 3.0 |
Dose-Response Relationship, Drug | 21 | 0.0 |
Electrophoresis, Polyacrylamide Gel | 14 | 0.0 |
Electrophysiology | 25 | 5.0 |
Forskolin/pharmacology | 31 | 8.0 |
Gene Deletion | 15 | 0.0 |
Genetic Vectors | 15 | 0.0 |
Genistein/pharmacology | 3 | 2.0 |
Hela Cells | 27 | 0.0 |
Models, Biological | 13 | 0.0 |
Models, Genetic | 4 | 0.0 |
Molecular Sequence Data | 130 | 0.0 |
Mutagenesis, Site-Directed | 23 | 0.0 |
*Mutation | 65 | 1.0 |
Phenylalanine/chemistry | 2 | 6.0 |
Plasmids/metabolism | 7 | 0.0 |
Protein Structure, Tertiary | 17 | 0.0 |
Rats | 39 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 276 | 0.0 |
Sequence Homology, Amino Acid | 18 | 0.0 |
Transfection | 73 | 0.0 |
Biological Transport, Active | 5 | 2.0 |
Chlorides/metabolism | 43 | 46.0 |
Cystic Fibrosis Transmembrane Conductance Regulator/*drug effects | 2 | 100.0 |
Male | 185 | 0.0 |
Nasal Mucosa/physiopathology | 5 | 100.0 |
Cells, Cultured | 55 | 0.0 |
Cystic Fibrosis Transmembrane Conductance Regulator/*chemistry/metabolism | 4 | 100.0 |
*Protein Folding | 7 | 5.0 |
Adenocarcinoma | 6 | 5.0 |
Cystic Fibrosis Transmembrane Conductance Regulator/*genetics/metabolism | 18 | 94.0 |
Forskolin/*pharmacology | 5 | 17.0 |
Gene Expression Regulation/*drug effects | 6 | 0.0 |
Genes, Reporter | 10 | 0.0 |
Luciferases/genetics/metabolism | 2 | 0.0 |
Lung Neoplasms | 3 | 2.0 |
Promoter Regions (Genetics) | 12 | 0.0 |
Recombinant Fusion Proteins/genetics/metabolism | 3 | 0.0 |
Tetradecanoylphorbol Acetate/*pharmacology | 3 | 0.0 |
Tumor Cells, Cultured | 33 | 0.0 |
Cystic Fibrosis/genetics/metabolism | 7 | 87.0 |
Cystic Fibrosis Transmembrane Conductance Regulator/genetics/*metabolism | 46 | 90.0 |
Dimerization | 2 | 0.0 |
Electric Conductivity | 27 | 16.0 |
Ion Channel Gating/drug effects | 2 | 10.0 |
Protein Binding | 28 | 0.0 |
Sequence Deletion | 17 | 0.0 |
Two-Hybrid System Techniques | 2 | 0.0 |
*Gene Transfer Techniques | 21 | 5.0 |
Green Fluorescent Proteins | 3 | 0.0 |
Luminescent Proteins/genetics | 2 | 1.0 |
Microscopy, Fluorescence | 14 | 0.0 |
Organ Culture Techniques | 3 | 0.0 |
Transgenes | 6 | 1.0 |
CHO Cells | 10 | 0.0 |
DNA, Complementary/metabolism | 5 | 0.0 |
Endoplasmic Reticulum/metabolism | 10 | 3.0 |
Glycosylation | 20 | 2.0 |
Hamsters | 29 | 0.0 |
Heat-Shock Proteins 70/metabolism | 2 | 3.0 |
Immunohistochemistry | 33 | 0.0 |
Kinetics | 33 | 0.0 |
Molecular Chaperones/metabolism | 2 | 4.0 |
Mutation | 105 | 1.0 |
Precipitin Tests | 15 | 0.0 |
Protein Biosynthesis | 4 | 0.0 |
Protein Conformation | 15 | 0.0 |
Protein Folding | 16 | 3.0 |
Time Factors | 28 | 0.0 |
English Abstract | 28 | 0.0 |
Gene Frequency | 19 | 0.0 |
*Genetics, Population | 3 | 0.0 |
Heterozygote | 29 | 1.0 |
Introns | 16 | 0.0 |
*Polymorphism, Genetic | 9 | 0.0 |
*Alternative Splicing | 5 | 0.0 |
Exons | 27 | 0.0 |
Mice | 112 | 0.0 |
Sheep | 3 | 0.0 |
Aged | 21 | 0.0 |
Cystic Fibrosis/genetics/*metabolism | 13 | 81.0 |
Electrolytes/*metabolism | 2 | 28.0 |
Homozygote | 20 | 1.0 |
Osmolar Concentration | 2 | 0.0 |
Species Specificity | 12 | 0.0 |
Water-Electrolyte Balance | 3 | 4.0 |
Binding, Competitive | 3 | 0.0 |
Cell Membrane/metabolism | 25 | 1.0 |
Cystic Fibrosis Transmembrane Conductance Regulator/*metabolism | 45 | 91.0 |
Exocytosis | 3 | 4.0 |
Fluorescent Antibody Technique | 8 | 0.0 |
Immunoblotting | 14 | 0.0 |
Membrane Proteins/*metabolism | 15 | 3.0 |
Reverse Transcriptase Polymerase Chain Reaction | 26 | 0.0 |
Xenopus | 14 | 2.0 |
Cystic Fibrosis/*therapy | 10 | 83.0 |
Epithelial Cells | 15 | 3.0 |
RNA, Messenger/analysis | 18 | 0.0 |
Transfection/methods | 2 | 1.0 |
Binding Sites | 18 | 0.0 |
Bronchoalveolar Lavage Fluid | 2 | 4.0 |
*Gastrointestinal Hormones | 3 | 30.0 |
Lung/cytology/*metabolism | 2 | 6.0 |
Peptides/metabolism | 2 | 0.0 |
Respiratory Mucosa/cytology/*metabolism | 3 | 30.0 |
Signal Transduction | 15 | 0.0 |
Comparative Study | 58 | 0.0 |
Cystic Fibrosis/*epidemiology/*genetics | 3 | 100.0 |
Genetics, Population | 4 | 1.0 |
Incidence | 5 | 0.0 |
Infant, Newborn | 22 | 0.0 |
Mutation/*genetics | 23 | 1.0 |
Argentina | 2 | 4.0 |
Cystic Fibrosis/diagnosis/*genetics | 6 | 66.0 |
Genetic Heterogeneity | 2 | 0.0 |
*Genetic Screening | 4 | 2.0 |
Polymorphism, Genetic | 21 | 0.0 |
Aged, 80 and over | 7 | 0.0 |
Infertility, Male/*genetics | 7 | 16.0 |
Vas Deferens/abnormalities | 13 | 92.0 |
Insects | 2 | 1.0 |
Microscopy, Confocal | 8 | 0.0 |
Oligonucleotides, Antisense/pharmacology | 3 | 1.0 |
Peptides/chemistry | 2 | 0.0 |
Protein Kinase C/*metabolism | 6 | 2.0 |
Recombinant Proteins/metabolism | 14 | 0.0 |
Cytosol/metabolism | 4 | 0.0 |
Models, Molecular | 11 | 0.0 |
Phosphorylation | 33 | 0.0 |
Protein Structure, Secondary | 7 | 0.0 |
Gene Therapy | 22 | 6.0 |
Immunoenzyme Techniques | 3 | 0.0 |
Mice, Inbred C57BL | 12 | 0.0 |
Mice, Inbred CFTR | 4 | 80.0 |
Nitric-Oxide Synthase/metabolism | 2 | 1.0 |
Receptors, Cell Surface/*metabolism | 3 | 0.0 |
beta-Galactosidase/genetics | 3 | 2.0 |
Chlorides/*pharmacokinetics | 2 | 100.0 |
Ion Channel Gating/*drug effects | 2 | 20.0 |
Membrane Potentials/drug effects | 10 | 7.0 |
Patch-Clamp Techniques | 42 | 10.0 |
Cystic Fibrosis/diagnosis/*epidemiology/*genetics | 2 | 100.0 |
Genetic Screening | 13 | 1.0 |
Pedigree | 11 | 0.0 |
Phenotype | 61 | 0.0 |
Residence Characteristics/statistics & numerical data | 2 | 33.0 |
Restriction Mapping | 8 | 0.0 |
Saudi Arabia/epidemiology | 2 | 11.0 |
Microscopy, Fluorescence/*methods | 2 | 15.0 |
Glutathione Transferase/metabolism | 5 | 0.0 |
Nerve Tissue Proteins/metabolism | 2 | 0.0 |
Recombinant Fusion Proteins/metabolism | 6 | 0.0 |
Adenosine Triphosphate/pharmacology | 6 | 8.0 |
Cystic Fibrosis Transmembrane Conductance Regulator/chemistry/*metabolism | 7 | 100.0 |
Models, Chemical | 4 | 1.0 |
Potassium Channels/metabolism | 4 | 11.0 |
Analysis of Variance | 3 | 0.0 |
Lung/physiopathology | 6 | 23.0 |
Cohort Studies | 5 | 0.0 |
Cystic Fibrosis/*diagnosis/*genetics | 5 | 83.0 |
Cystic Fibrosis Transmembrane Conductance Regulator/analysis/*genetics | 6 | 100.0 |
Genetic Markers | 5 | 0.0 |
Italy | 5 | 0.0 |
Neonatal Screening | 2 | 6.0 |
*Phenotype | 3 | 1.0 |
Sensitivity and Specificity | 7 | 0.0 |
Bicarbonates/*metabolism | 8 | 44.0 |
Cystic Fibrosis/metabolism | 23 | 74.0 |
Cystic Fibrosis Transmembrane Conductance Regulator/physiology | 6 | 100.0 |
Lung/metabolism/physiopathology | 3 | 100.0 |
Mucus/*secretion | 2 | 20.0 |
Cystic Fibrosis Transmembrane Conductance Regulator/genetics/physiology | 3 | 100.0 |
Disease Models, Animal | 12 | 0.0 |
Gene Transfer Techniques/adverse effects | 2 | 100.0 |
Cystic Fibrosis Transmembrane Conductance Regulator/*physiology | 20 | 95.0 |
Hydrogen-Ion Concentration | 11 | 0.0 |
Permeability | 5 | 3.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 22 | 0.0 |
Chlorides/*physiology | 2 | 50.0 |
Cystic Fibrosis Transmembrane Conductance Regulator/genetics/*physiology | 12 | 92.0 |
Base Sequence | 70 | 0.0 |
Blotting, Northern | 9 | 0.0 |
Cloning, Molecular | 12 | 0.0 |
Cystic Fibrosis/*metabolism | 26 | 55.0 |
Epithelial Cells/metabolism | 17 | 5.0 |
In Situ Hybridization | 18 | 0.0 |
Lung/metabolism | 8 | 4.0 |
Mucins/metabolism | 2 | 4.0 |
RNA, Messenger/metabolism | 26 | 0.0 |
Up-Regulation | 3 | 0.0 |
Cyclic AMP-Dependent Protein Kinases/metabolism | 15 | 7.0 |
Cytochalasin D/pharmacology | 3 | 3.0 |
Cyclic AMP-Dependent Protein Kinases/*metabolism | 7 | 7.0 |
4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid/pharmacology | 8 | 30.0 |
Biological Transport/drug effects/physiology | 5 | 15.0 |
Enzyme Inhibitors/pharmacology | 13 | 0.0 |
Nitric Oxide Donors/pharmacology | 2 | 3.0 |
Thapsigargin/pharmacology | 2 | 1.0 |
ATP-Binding Cassette Transporters/*metabolism | 2 | 2.0 |
Adenosine Triphosphate/*metabolism | 13 | 14.0 |
Diffusion | 4 | 4.0 |
Carrier Proteins/*genetics/metabolism | 2 | 0.0 |
Chromosomes, Human, Pair 7 | 4 | 2.0 |
Gene Expression Regulation | 18 | 0.0 |
In Situ Hybridization, Fluorescence | 5 | 0.0 |
*Transcription, Genetic | 8 | 0.0 |
Down-Regulation | 6 | 0.0 |
Ion Transport/drug effects | 7 | 19.0 |
Nasal Mucosa/metabolism/pathology | 2 | 33.0 |
Nasal Polyps/*metabolism/pathology | 2 | 16.0 |
*Gene Expression Regulation | 7 | 0.0 |
RNA, Messenger | 2 | 0.0 |
Tissue Distribution | 15 | 0.0 |
Chlorides/*analysis | 2 | 100.0 |
Double-Blind Method | 7 | 0.0 |
Membrane Potentials | 27 | 13.0 |
Multicenter Studies | 2 | 1.0 |
Randomized Controlled Trials | 2 | 0.0 |
Reproducibility of Results | 5 | 0.0 |
Sweat/*chemistry | 3 | 75.0 |
Cystic Fibrosis/genetics | 20 | 66.0 |
Oligospermia/genetics | 2 | 11.0 |
Risk Factors | 6 | 0.0 |
Vas Deferens/*abnormalities | 22 | 95.0 |
Chloride Channels/drug effects/*physiology | 3 | 60.0 |
Codon | 2 | 0.0 |
Cyclic AMP/pharmacology | 18 | 16.0 |
Cyclic AMP-Dependent Protein Kinases/pharmacology | 4 | 36.0 |
Cystic Fibrosis/*physiopathology | 3 | 23.0 |
Ionomycin/pharmacology | 4 | 1.0 |
Chronic Disease | 18 | 1.0 |
Genetic Predisposition to Disease/genetics | 2 | 0.0 |
*Trypsin | 5 | 18.0 |
Trypsin Inhibitor, Kazal Pancreatic/genetics | 2 | 66.0 |
Trypsinogen/genetics | 4 | 44.0 |
Cystic Fibrosis/complications/*diagnosis/genetics | 2 | 100.0 |
Cystic Fibrosis Transmembrane Conductance Regulator/genetics | 42 | 63.0 |
Diagnosis, Differential | 5 | 0.0 |
European Continental Ancestry Group/*genetics | 2 | 0.0 |
Prevalence | 6 | 0.0 |
Recurrence | 3 | 0.0 |
Cystic Fibrosis/*complications | 3 | 42.0 |
Lung Diseases/genetics | 2 | 50.0 |
Mutation/*physiology | 4 | 3.0 |
Cystic Fibrosis/*genetics | 80 | 80.0 |
Epithelium/metabolism | 33 | 8.0 |
*Genetic Predisposition to Disease | 2 | 0.0 |
Ion Transport | 14 | 20.0 |
Pancreatitis/*genetics | 6 | 17.0 |
Sweat/metabolism | 3 | 50.0 |
Clinical Trials | 5 | 0.0 |
*Gene Therapy | 16 | 4.0 |
Nasal Mucosa | 2 | 40.0 |
Rabbits | 17 | 0.0 |
Safety | 2 | 1.0 |
Structure-Activity Relationship | 13 | 0.0 |
Treatment Outcome | 5 | 0.0 |
DNA/genetics | 10 | 0.0 |
DNA Primers | 16 | 0.0 |
Genes, Structural | 4 | 0.0 |
Polymerase Chain Reaction | 59 | 0.0 |
Sequence Analysis, DNA | 10 | 0.0 |
Autistic Disorder/*genetics | 2 | 3.0 |
Carrier Proteins/*genetics | 4 | 0.0 |
Chromosomes, Human, Pair 7/*genetics | 3 | 2.0 |
DNA Mutational Analysis | 27 | 0.0 |
DNA, Complementary/chemistry/genetics | 2 | 0.0 |
Genetic Predisposition to Disease | 5 | 0.0 |
Nerve Tissue Proteins/*genetics | 2 | 0.0 |
Point Mutation | 9 | 0.0 |
RNA, Messenger/genetics/metabolism | 6 | 0.0 |
Sequence Alignment | 13 | 0.0 |
Calcium/metabolism | 6 | 0.0 |
Intestinal Absorption | 2 | 1.0 |
Mice, Knockout | 9 | 0.0 |
Cystic Fibrosis Transmembrane Conductance Regulator/*biosynthesis | 2 | 100.0 |
Adenosine Triphosphate/metabolism | 15 | 3.0 |
Biological Transport | 16 | 1.0 |
Cysteine Endopeptidases/*metabolism | 2 | 0.0 |
Glycerol/pharmacology | 2 | 18.0 |
In Vitro | 29 | 0.0 |
Leupeptins/pharmacology | 3 | 2.0 |
Lipid Bilayers/metabolism | 7 | 25.0 |
Multienzyme Complexes/*metabolism | 2 | 1.0 |
Proteasome Endopeptidase Complex | 7 | 1.0 |
Trypsin/pharmacology | 2 | 1.0 |
Ubiquitins/metabolism | 2 | 1.0 |
Chile | 2 | 3.0 |
Caco-2 Cells | 5 | 1.0 |
Chloride Channels/analysis/*physiology | 2 | 100.0 |
Chlorides/*metabolism | 30 | 44.0 |
Intestinal Mucosa/*metabolism | 5 | 6.0 |
*Evolution | 2 | 1.0 |
Nutritional Status | 4 | 2.0 |
Cell Division | 3 | 0.0 |
Cytoskeleton/metabolism | 2 | 0.0 |
Amiloride/pharmacology | 10 | 29.0 |
Chloride Channels/antagonists & inhibitors | 2 | 40.0 |
Cystic Fibrosis Transmembrane Conductance Regulator/metabolism | 7 | 58.0 |
Mice, Inbred Strains | 4 | 0.0 |
Thionucleotides/pharmacology | 5 | 8.0 |
Kidney/metabolism | 3 | 0.0 |
1-Methyl-3-isobutylxanthine/pharmacology | 8 | 8.0 |
Dogs | 9 | 0.0 |
Phosphodiesterase Inhibitors/pharmacology | 7 | 6.0 |
Pulmonary Circulation/physiology | 2 | 25.0 |
Amino Acid Substitution | 3 | 0.0 |
Bronchi/cytology/metabolism | 2 | 13.0 |
Oocytes/metabolism | 7 | 3.0 |
Sodium/metabolism | 9 | 6.0 |
Sodium Channels/genetics/*metabolism | 5 | 41.0 |
Xenopus laevis | 18 | 4.0 |
DNA/chemistry/genetics | 2 | 0.0 |
Mutation, Missense | 5 | 0.0 |
*Phylogeny | 2 | 1.0 |
Sequence Homology, Nucleic Acid | 8 | 0.0 |
Adenoviridae/*genetics | 6 | 2.0 |
DNA, Recombinant | 2 | 1.0 |
Transduction, Genetic | 4 | 1.0 |
*Transfection | 7 | 2.0 |
Gene Therapy/adverse effects/*methods | 2 | 28.0 |
Genetic Vectors/*administration & dosage | 2 | 8.0 |
Tomography, X-Ray Computed | 2 | 0.0 |
DNA/metabolism | 4 | 0.0 |
Oligonucleotides/metabolism | 2 | 2.0 |
RNA/metabolism | 2 | 0.0 |
Ultraviolet Rays | 3 | 0.0 |
ATP-Binding Cassette Transporters/*genetics | 2 | 0.0 |
*Gene Expression | 11 | 1.0 |
Multidrug Resistance-Associated Proteins | 2 | 2.0 |
Body Height | 4 | 2.0 |
Body Weight | 4 | 0.0 |
Europe | 2 | 0.0 |
*Homozygote | 5 | 3.0 |
Mutation/genetics | 13 | 1.0 |
Predictive Value of Tests | 3 | 0.0 |
Prognosis | 4 | 0.0 |
Registries | 2 | 0.0 |
Acute Disease | 3 | 0.0 |
Exons/genetics | 8 | 0.0 |
Introns/genetics | 4 | 0.0 |
*Polymorphism, Single-Stranded Conformational | 3 | 2.0 |
Chromosomes, Artificial, Yeast | 2 | 0.0 |
DNA-Binding Proteins/metabolism | 3 | 0.0 |
Deoxyribonuclease I/metabolism | 4 | 2.0 |
*Introns | 7 | 3.0 |
Mice, Transgenic | 18 | 0.0 |
*Regulatory Sequences, Nucleic Acid | 3 | 0.0 |
Transcription, Genetic | 18 | 0.0 |
Cystic Fibrosis Transmembrane Conductance Regulator/analysis/*metabolism | 2 | 100.0 |
Gene Expression/physiology | 3 | 0.0 |
Signal Transduction/physiology | 3 | 0.0 |
Enzyme Activation | 5 | 0.0 |
*Alleles | 8 | 0.0 |
Lymphocytes | 2 | 1.0 |
Pregnancy | 9 | 0.0 |
Adenosine Triphosphate/*blood | 2 | 25.0 |
Pancreas/*metabolism | 2 | 5.0 |
RNA, Messenger/*analysis | 4 | 0.0 |
Molecular Weight | 3 | 0.0 |
Point Mutation/genetics | 3 | 1.0 |
Thermodynamics | 3 | 0.0 |
Nucleic Acid Hybridization | 5 | 0.0 |
Sequence Analysis, DNA/*methods | 3 | 4.0 |
Chromosome Mapping | 8 | 0.0 |
Genome | 2 | 0.0 |
Microsatellite Repeats | 4 | 0.0 |
Oocytes | 12 | 11.0 |
DNA Primers/chemistry | 6 | 0.0 |
Membrane Proteins/biosynthesis/*genetics | 5 | 11.0 |
RNA, Messenger/*biosynthesis | 3 | 1.0 |
Cysteine Endopeptidases | 2 | 4.0 |
Isoxazoles/pharmacology | 2 | 13.0 |
Multienzyme Complexes/antagonists & inhibitors | 2 | 7.0 |
Protein Processing, Post-Translational/*drug effects | 2 | 3.0 |
Protein Synthesis Inhibitors/pharmacology | 3 | 0.0 |
Epithelial Cells/*metabolism | 4 | 3.0 |
Trans-Activation (Genetics) | 4 | 0.0 |
beta-Galactosidase/metabolism | 2 | 1.0 |
Crystallization | 2 | 0.0 |
Ligands | 3 | 0.0 |
Protein Structure, Quaternary | 2 | 1.0 |
Substrate Specificity | 3 | 0.0 |
RNA, Messenger/analysis/genetics | 4 | 0.0 |
Syndrome | 3 | 0.0 |
Transgenes/genetics | 3 | 3.0 |
Fluorescent Dyes/metabolism | 2 | 2.0 |
Tumor Necrosis Factor-alpha/pharmacology | 2 | 0.0 |
Chloride Channels/metabolism | 14 | 77.0 |
Isoproterenol/pharmacology | 9 | 8.0 |
Cyclic AMP/analogs & derivatives/pharmacology | 2 | 25.0 |
Membrane Potentials/drug effects/physiology | 10 | 13.0 |
Oocytes/physiology | 6 | 5.0 |
Protein Kinase C/metabolism | 6 | 1.0 |
Protein Transport/drug effects/physiology | 2 | 10.0 |
Homeostasis | 4 | 1.0 |
Pancreatic Ducts/*metabolism | 2 | 66.0 |
Phylogeny | 5 | 0.0 |
Recombinant Proteins/chemistry/metabolism | 5 | 0.0 |
Survival Analysis | 4 | 0.0 |
Recombinant Proteins/genetics/metabolism | 7 | 1.0 |
DNA, Satellite/*genetics | 2 | 3.0 |
Haplotypes | 8 | 0.0 |
Linkage (Genetics) | 4 | 0.0 |
Sodium-Potassium-Chloride Symporters | 2 | 15.0 |
DNA | 9 | 0.0 |
Polymerase Chain Reaction/methods | 9 | 0.0 |
Preimplantation Diagnosis/*methods | 2 | 11.0 |
Sweat Glands/*metabolism | 4 | 66.0 |
Golgi Apparatus/metabolism | 4 | 2.0 |
Microscopy, Immunoelectron | 2 | 0.0 |
3T3 Cells | 12 | 0.0 |
Cell Line, Tumor | 3 | 0.0 |
Repressor Proteins/*physiology | 2 | 1.0 |
Organ Specificity | 5 | 0.0 |
Cyclic AMP/*physiology | 7 | 8.0 |
GTP-Binding Proteins/*physiology | 2 | 1.0 |
Guanosine 5'-O-(3-Thiotriphosphate)/pharmacology | 3 | 4.0 |
Biological Transport/physiology | 3 | 1.0 |
Chlorides/antagonists & inhibitors/*metabolism | 3 | 100.0 |
Mutation/physiology | 5 | 4.0 |
Reference Values | 7 | 0.0 |
Trachea/cytology/*metabolism | 2 | 18.0 |
Cystic Fibrosis/ethnology/*genetics | 4 | 100.0 |
DNA Mutational Analysis/*methods | 4 | 3.0 |
Genetic Screening/methods | 3 | 2.0 |
Na(+)-K(+)-Exchanging ATPase/metabolism | 2 | 4.0 |
Sodium Channels/metabolism | 3 | 50.0 |
Nasal Mucosa/*metabolism | 6 | 31.0 |
Carrier Proteins/genetics/*metabolism | 2 | 0.0 |
*Ligases | 2 | 1.0 |
Multienzyme Complexes/antagonists & inhibitors/*metabolism | 2 | 9.0 |
Protein Structure, Tertiary/physiology | 3 | 1.0 |
*Ubiquitin-Protein Ligases | 3 | 0.0 |
Gene Expression Regulation/*physiology | 2 | 0.0 |
Polymorphism, Restriction Fragment Length | 6 | 0.0 |
Smoking | 2 | 0.0 |
Cystic Fibrosis/genetics/*metabolism/physiopathology | 2 | 66.0 |
Gene Frequency/genetics | 2 | 0.0 |
Drug Synergism | 2 | 0.0 |
Rats, Inbred F344 | 3 | 0.0 |
Cell Line, Transformed | 8 | 0.0 |
Fetus | 4 | 0.0 |
Hydrogen Peroxide/pharmacology | 3 | 1.0 |
Pigment Epithelium of Eye/cytology/drug effects/*metabolism | 2 | 18.0 |
Age of Onset | 2 | 0.0 |
Lung Diseases/*genetics | 2 | 20.0 |
Sweat/chemistry/secretion | 2 | 100.0 |
Gene Library | 3 | 0.0 |
Oligonucleotide Probes/genetics | 2 | 1.0 |
Diuretics/pharmacology | 3 | 30.0 |
Stilbenes/pharmacology | 3 | 9.0 |
Swine | 4 | 0.0 |
Tetrodotoxin/pharmacology | 2 | 5.0 |
Vasoactive Intestinal Peptide/pharmacology | 2 | 2.0 |
Adenylyl Imidodiphosphate/pharmacology | 4 | 66.0 |
Hydrolysis | 8 | 1.0 |
Magnesium/pharmacology | 3 | 2.0 |
Interleukin-1/metabolism | 2 | 0.0 |
Mice, Inbred BALB C | 3 | 0.0 |
Pseudomonas aeruginosa/physiology | 2 | 33.0 |
*Genotype | 2 | 0.0 |
Sodium Channels/*physiology | 3 | 30.0 |
Gene Dosage | 2 | 0.0 |
*Prenatal Diagnosis | 3 | 1.0 |
Age Factors | 7 | 0.0 |
Cystic Fibrosis Transmembrane Conductance Regulator/*analysis | 2 | 100.0 |
Fluorescent Antibody Technique, Indirect | 6 | 0.0 |
Multigene Family | 2 | 0.0 |
Drug Resistance, Multiple | 2 | 1.0 |
Polymorphism, Single-Stranded Conformational | 7 | 0.0 |
Chromosome Deletion | 4 | 0.0 |
France/epidemiology | 3 | 2.0 |
Infertility, Male/epidemiology/genetics | 2 | 100.0 |
Mutation, Missense/genetics | 2 | 1.0 |
Polymorphism, Genetic/genetics | 6 | 0.0 |
Bacterial Adhesion | 3 | 4.0 |
Epithelium/chemistry | 4 | 3.0 |
Liposomes | 7 | 2.0 |
Phosphatidylethanolamines | 2 | 11.0 |
Cystic Fibrosis/*metabolism/pathology | 2 | 25.0 |
Liver/*chemistry | 2 | 5.0 |
Anions/*metabolism | 3 | 50.0 |
Anthranilic Acids/pharmacology | 3 | 60.0 |
Calcium Channel Blockers/pharmacology | 3 | 3.0 |
Glyburide/pharmacology | 5 | 26.0 |
Nitrobenzoates/pharmacology | 2 | 22.0 |
Nystatin/pharmacology | 2 | 16.0 |
Sodium Channels/*metabolism | 4 | 19.0 |
Karyotyping | 3 | 0.0 |
*Linkage (Genetics) | 2 | 0.0 |
*Amino Acid Transport Systems, Basic | 2 | 5.0 |
*Bacterial Proteins | 2 | 1.0 |
Membrane Proteins/metabolism | 6 | 1.0 |
Gene Transfer Techniques | 10 | 1.0 |
*Genetic Vectors | 14 | 4.0 |
Prospective Studies | 5 | 0.0 |
Severity of Illness Index | 4 | 0.0 |
Kidney/abnormalities | 2 | 10.0 |
*Mutation/genetics | 2 | 6.0 |
*Variation (Genetics) | 2 | 0.0 |
Cyclic AMP/physiology | 6 | 5.0 |
Gene Expression Regulation/physiology | 2 | 0.0 |
Membrane Proteins/genetics | 10 | 2.0 |
*DNA Mutational Analysis | 3 | 1.0 |
Genetic Predisposition to Disease/*genetics | 3 | 0.0 |
Pancreatitis/diagnosis/*genetics | 2 | 33.0 |
Testis/metabolism | 2 | 0.0 |
Frameshift Mutation | 3 | 0.0 |
Heteroduplex Analysis | 2 | 2.0 |
Gene Therapy/methods | 3 | 3.0 |
Ethnic Groups/genetics | 2 | 1.0 |
Alternative Splicing/genetics | 3 | 1.0 |
Enhancer Elements (Genetics) | 3 | 0.0 |
Exons/*genetics | 4 | 1.0 |
RNA, Messenger/genetics | 13 | 0.0 |
Transcription, Genetic/genetics | 2 | 0.0 |
Cell Compartmentation | 4 | 1.0 |
Endocytosis/drug effects | 2 | 3.0 |
Chloride Channels/physiology | 4 | 66.0 |
Ion Channel Gating | 13 | 18.0 |
Arginine/genetics | 3 | 1.0 |
*Gene Deletion | 3 | 0.0 |
Oligospermia/diagnosis/genetics | 2 | 100.0 |
Protein Processing, Post-Translational/genetics | 2 | 10.0 |
Conserved Sequence | 2 | 0.0 |
Cystic Fibrosis Transmembrane Conductance Regulator/*genetics/*metabolism | 8 | 100.0 |
*Exons | 9 | 2.0 |
Gene Amplification | 2 | 0.0 |
Repetitive Sequences, Nucleic Acid | 2 | 0.0 |
Vas Deferens/*abnormalities/metabolism | 2 | 100.0 |
Interleukin-8/metabolism | 2 | 1.0 |
Trypsin/metabolism | 3 | 2.0 |
Cystic Fibrosis/complications/*genetics | 4 | 80.0 |
Temperature | 6 | 0.0 |
Chloride Channels/drug effects | 4 | 66.0 |
*Mutation, Missense | 3 | 0.0 |
Anti-Inflammatory Agents/therapeutic use | 2 | 2.0 |
Cystic Fibrosis/*genetics/*physiopathology/therapy | 2 | 100.0 |
Anions/metabolism | 8 | 42.0 |
Anti-Inflammatory Agents, Non-Steroidal/*pharmacology | 2 | 1.0 |
Cell Survival/drug effects | 2 | 0.0 |
Recombinant Proteins/biosynthesis | 4 | 0.0 |
RNA, Messenger/*metabolism | 2 | 0.0 |
Respiratory System/*metabolism | 2 | 14.0 |
Tumor Cells, Cultured/drug effects/metabolism/pathology | 2 | 5.0 |
Carrier Proteins/*metabolism | 2 | 0.0 |
*Genes, Structural | 3 | 0.0 |
Mice/*genetics | 2 | 0.0 |
Regulatory Sequences, Nucleic Acid | 4 | 0.0 |
Base Sequence/genetics | 2 | 0.0 |
Molecular Conformation | 3 | 1.0 |
Membrane Proteins/genetics/*metabolism | 9 | 3.0 |
Cell Membrane/*metabolism | 2 | 0.0 |
Light | 2 | 0.0 |
Protein Transport | 6 | 0.0 |
Bronchi/*metabolism | 3 | 9.0 |
Protein Structure, Tertiary/genetics | 3 | 1.0 |
Staining and Labeling | 2 | 0.0 |
*Tumor Suppressor Proteins | 2 | 0.0 |
Exocrine Pancreatic Insufficiency/genetics | 2 | 100.0 |
Chlorides/pharmacokinetics | 2 | 50.0 |
Sodium/pharmacokinetics | 2 | 66.0 |
Phosphoprotein Phosphatase/metabolism | 2 | 2.0 |
Cell Membrane Permeability | 6 | 3.0 |
Sodium Chloride/metabolism | 2 | 16.0 |
RNA, Messenger/*biosynthesis/genetics | 2 | 3.0 |
Cystic Fibrosis/complications/*genetics/physiopathology | 2 | 100.0 |
Genetic Complementation Test | 5 | 0.0 |
Asthma/*genetics | 2 | 3.0 |
Fibroblasts/metabolism | 2 | 0.0 |
Lung/*metabolism | 4 | 4.0 |
Magnetic Resonance Spectroscopy | 2 | 0.0 |
Oligosaccharides/metabolism | 2 | 4.0 |
Spectrometry, Mass, Fast Atom Bombardment | 2 | 7.0 |
alpha-L-Fucosidase/genetics/metabolism | 2 | 100.0 |
Cystic Fibrosis Transmembrane Conductance Regulator/chemistry/*genetics | 3 | 100.0 |
Electrophoresis, Agar Gel | 4 | 0.0 |
Nucleic Acid Conformation | 4 | 0.0 |
Epithelial Cells/physiology | 3 | 4.0 |
Recombinant Fusion Proteins/chemistry/metabolism | 2 | 1.0 |
*Sodium-Hydrogen Antiporter | 3 | 27.0 |
Bronchi | 2 | 16.0 |
Colon | 2 | 7.0 |
*Meconium | 2 | 66.0 |
Retrospective Studies | 6 | 0.0 |
*Ion Channel Gating | 2 | 12.0 |
Respiratory System/cytology/*metabolism | 2 | 25.0 |
Adenovirus E4 Proteins/*genetics | 2 | 50.0 |
Variation (Genetics) | 10 | 0.0 |
Cystic Fibrosis/*genetics/*therapy | 3 | 75.0 |
Dependovirus/*genetics | 3 | 3.0 |
*Promoter Regions (Genetics) | 7 | 0.0 |
DNA, Complementary/analysis/genetics | 2 | 2.0 |
Lipids | 3 | 15.0 |
Nasal Mucosa/metabolism | 3 | 27.0 |
Chromatography, High Pressure Liquid/methods | 2 | 1.0 |
Proteins/genetics | 3 | 0.0 |
Repressor Proteins/genetics | 2 | 1.0 |
Recombinant Proteins/biosynthesis/metabolism | 2 | 1.0 |
*Sequence Deletion | 8 | 2.0 |
DNA Footprinting | 3 | 1.0 |
Deoxyribonuclease I/*metabolism | 2 | 11.0 |
Kidney/cytology/*metabolism | 2 | 9.0 |
Nitroso Compounds/pharmacology | 2 | 11.0 |
Heterozygote Detection | 6 | 1.0 |
Dinucleotide Repeats/genetics | 2 | 4.0 |
Cell Polarity | 2 | 1.0 |
Tetradecanoylphorbol Acetate/pharmacology | 3 | 0.0 |
Alkaline Phosphatase/genetics/metabolism | 2 | 11.0 |
Bronchi/cytology/*metabolism | 3 | 21.0 |
Cation Exchange Resins | 2 | 22.0 |
Drug Carriers | 2 | 1.0 |
*Liposomes | 2 | 5.0 |
Transfection/*methods | 3 | 5.0 |
Mucus/secretion | 2 | 25.0 |
Electrophoresis, Capillary | 2 | 4.0 |
Chloride Channels/*physiology | 5 | 55.0 |
Case-Control Studies | 6 | 0.0 |
Cystic Fibrosis/*genetics/metabolism | 5 | 100.0 |
Intestines/metabolism | 4 | 3.0 |
Respiratory System/metabolism | 3 | 30.0 |
Sweat Glands/metabolism | 2 | 28.0 |
Antibodies/pharmacology | 2 | 0.0 |
*Sodium Channel Blockers | 2 | 22.0 |
DNA, Complementary/*administration & dosage | 2 | 25.0 |
Cystic Fibrosis Transmembrane Conductance Regulator/*analysis/genetics | 3 | 100.0 |
Glyceraldehyde-3-Phosphate Dehydrogenases/analysis/genetics | 2 | 100.0 |
Keratin/analysis | 2 | 0.0 |
Myocardium/*metabolism | 4 | 1.0 |
RNA, Complementary/genetics | 2 | 22.0 |
Recombinant Proteins/chemistry/genetics/metabolism | 2 | 0.0 |
Isoenzymes/metabolism | 2 | 0.0 |
Lysophosphatidylcholines/metabolism | 2 | 15.0 |
Phospholipases A/*metabolism | 2 | 4.0 |
Photoaffinity Labels | 2 | 12.0 |
*Potassium Channels, Inwardly Rectifying | 3 | 6.0 |
Heat-Shock Proteins/*metabolism | 2 | 3.0 |
Pancreatic Neoplasms | 2 | 5.0 |
Transcription Factors/metabolism | 4 | 0.0 |
Chloride Channels/*metabolism | 3 | 23.0 |
Genetic Counseling | 2 | 1.0 |
COS Cells | 8 | 0.0 |
Epithelial Cells/microbiology | 2 | 8.0 |
Flow Cytometry | 2 | 0.0 |
Inflammation | 2 | 0.0 |
Lung/metabolism/*physiopathology | 2 | 100.0 |
Cystic Fibrosis Transmembrane Conductance Regulator/chemistry/*physiology | 2 | 100.0 |
Ion Channels/*metabolism | 2 | 4.0 |
Italy/epidemiology | 2 | 0.0 |
DNA, Complementary/genetics | 9 | 0.0 |
Adrenergic beta-Agonists/pharmacology | 4 | 8.0 |
Colon/drug effects/metabolism | 2 | 28.0 |
Epithelium/drug effects/metabolism | 2 | 3.0 |
Kidney | 3 | 0.0 |
*Point Mutation | 12 | 0.0 |
Genistein/*pharmacology | 3 | 9.0 |
Cytosol/*metabolism | 2 | 6.0 |
Endoplasmic Reticulum/*metabolism | 2 | 1.0 |
DNA Mutational Analysis/*standards | 2 | 40.0 |
Quality Control | 4 | 2.0 |
Lung/*metabolism/pathology | 2 | 9.0 |
*Heterozygote | 2 | 0.0 |
Transcription Factors/genetics | 2 | 0.0 |
Membrane Potentials/physiology | 5 | 5.0 |
DNA-Binding Protein, Cyclic AMP-Responsive/*metabolism | 2 | 2.0 |
Oxazoles/pharmacology | 2 | 5.0 |
Xanthines/pharmacology | 2 | 12.0 |
Chlorides/analysis/metabolism | 2 | 100.0 |
DNA/analysis | 7 | 0.0 |
Epithelium/physiopathology | 2 | 66.0 |
Follow-Up Studies | 2 | 0.0 |
Sweat/chemistry | 8 | 80.0 |
Gene Expression/drug effects | 3 | 0.0 |
Biological Transport/drug effects | 2 | 0.0 |
Potassium/metabolism | 6 | 5.0 |
Genetic Engineering | 2 | 2.0 |
Microscopy, Electron | 6 | 0.0 |
Plasmids | 9 | 0.0 |
Pseudomonas aeruginosa/*physiology | 2 | 40.0 |
Adenoviridae/genetics | 5 | 1.0 |
Tumor Necrosis Factor-alpha/*pharmacology | 2 | 0.0 |
RNA Splicing/genetics | 3 | 2.0 |
Mutagenesis, Insertional/*genetics | 2 | 6.0 |
Sequence Deletion/*genetics | 2 | 1.0 |
Antibody Specificity | 2 | 0.0 |
Enzyme-Linked Immunosorbent Assay | 3 | 0.0 |
*Membrane Proteins | 2 | 0.0 |
Calcium/pharmacology | 3 | 1.0 |
*Bacterial Adhesion | 2 | 4.0 |
Cell Nucleus/metabolism | 2 | 0.0 |
Protease Inhibitors/pharmacology | 3 | 1.0 |
Trachea/*metabolism | 4 | 23.0 |
Cystic Fibrosis/*genetics/physiopathology | 11 | 84.0 |
*Saccharomyces cerevisiae Proteins | 2 | 0.0 |
Colon/microbiology | 2 | 40.0 |
Epithelium/microbiology | 2 | 9.0 |
Recombinant Proteins | 8 | 1.0 |
Peptide Hydrolases/metabolism | 2 | 1.0 |
Protein Processing, Post-Translational | 4 | 0.0 |
Oligospermia/*genetics | 5 | 10.0 |
Fluorescence | 4 | 1.0 |
Cattle | 5 | 0.0 |
Cell Transplantation | 2 | 2.0 |
Transplantation, Heterologous | 4 | 0.0 |
Chromatography, High Pressure Liquid/*methods | 3 | 2.0 |
Evaluation Studies | 2 | 0.0 |
Nucleic Acid Denaturation | 3 | 3.0 |
Proto-Oncogene Proteins/genetics | 2 | 0.0 |
Intestine, Small/metabolism | 3 | 5.0 |
RNA, Messenger/biosynthesis | 3 | 0.0 |
Xanthines/*pharmacology | 3 | 42.0 |
Spodoptera | 4 | 1.0 |
Escherichia coli/genetics | 3 | 0.0 |
Recombinant Fusion Proteins/chemistry/genetics/metabolism | 3 | 1.0 |
Microscopy, Fluorescence/methods | 2 | 6.0 |
Vasoactive Intestinal Peptide/*pharmacology | 2 | 2.0 |
DNA, Single-Stranded | 3 | 3.0 |
Promoter Regions (Genetics)/genetics | 2 | 0.0 |
Endopeptidases/*metabolism | 3 | 2.0 |
Microsomes/metabolism | 3 | 2.0 |
Peptide Mapping | 4 | 0.0 |
Chlorides/analysis | 3 | 50.0 |
Nasal Cavity/physiopathology | 2 | 66.0 |
*Chromosome Mapping | 2 | 0.0 |
DNA, Complementary | 8 | 0.0 |
Hybrid Cells | 4 | 0.0 |
Epithelium/physiology | 6 | 7.0 |
Lac Operon | 2 | 1.0 |
*Genetic Markers | 2 | 0.0 |
Adenoviridae | 2 | 2.0 |
Chlorides/physiology | 3 | 60.0 |
Codon, Terminator | 2 | 3.0 |
Diphosphates/pharmacology | 2 | 66.0 |
Lipid Bilayers | 6 | 14.0 |
Autoradiography | 2 | 0.0 |
Cystic Fibrosis Transmembrane Conductance Regulator/biosynthesis/genetics | 2 | 66.0 |
Drug Resistance, Multiple/*genetics | 2 | 3.0 |
Image Processing, Computer-Assisted | 4 | 1.0 |
Rats, Sprague-Dawley | 3 | 0.0 |
Vas Deferens/*chemistry | 2 | 100.0 |
Antibodies, Monoclonal | 3 | 0.0 |
Cell Differentiation | 2 | 0.0 |
RNA-Directed DNA Polymerase | 2 | 1.0 |
Genetic Vectors/genetics | 4 | 1.0 |
Lac Operon/genetics | 2 | 7.0 |
Biological Markers | 2 | 0.0 |
Biopsy | 2 | 0.0 |
Cytoskeletal Proteins/metabolism | 2 | 0.0 |
Carbachol/pharmacology | 2 | 2.0 |
Chromosomes, Artificial, Yeast/genetics | 2 | 1.0 |
Pancreatic Ducts/metabolism | 3 | 42.0 |
Recombination, Genetic | 5 | 0.0 |
Cystic Fibrosis/*pathology | 2 | 100.0 |
Pregnancy Trimester, Second | 2 | 0.0 |
*Chromosomes, Artificial, Yeast | 2 | 3.0 |
Bacterial Adhesion/*physiology | 2 | 9.0 |
Liposomes/chemistry | 2 | 15.0 |
Microscopy, Electron, Scanning | 2 | 0.0 |
DNA/*analysis | 2 | 0.0 |
Collagen/genetics | 2 | 2.0 |
Nephritis, Hereditary/genetics | 2 | 25.0 |
Silver Staining | 2 | 2.0 |
Cyclic AMP/*pharmacology | 4 | 7.0 |
Phosphoric Monoester Hydrolases/antagonists & inhibitors | 2 | 18.0 |
5' Untranslated Regions/genetics | 2 | 1.0 |
Sequence Deletion/genetics | 3 | 1.0 |
Prenatal Diagnosis | 2 | 1.0 |
Gene Expression Regulation/genetics | 2 | 1.0 |
Sodium/*metabolism | 3 | 4.0 |
Transformation, Genetic | 2 | 1.0 |
European Continental Ancestry Group/genetics | 2 | 0.0 |
Ion Channels/*physiology | 2 | 6.0 |
Cystic Fibrosis/epidemiology/*genetics | 8 | 100.0 |
Chloride Channels/drug effects/*metabolism | 2 | 66.0 |
Guinea Pigs | 2 | 0.0 |
Gene Expression/genetics | 3 | 1.0 |
RNA Processing, Post-Transcriptional | 2 | 1.0 |
Mutagenesis | 5 | 0.0 |
Probability | 2 | 0.0 |
Cell Membrane/physiology | 4 | 2.0 |
Defective Viruses/genetics | 2 | 13.0 |
Epithelium | 4 | 6.0 |
Ion Channels/drug effects/*metabolism | 2 | 50.0 |
Consensus Sequence | 3 | 0.0 |
*Sequence Tagged Sites | 2 | 5.0 |
Pancreas/physiopathology | 5 | 55.0 |
Immunohistochemistry/*methods | 2 | 2.0 |
Ion Channel Gating/physiology | 3 | 13.0 |
Protein Kinases/metabolism | 7 | 1.0 |
Blotting, Southern | 3 | 0.0 |
Endosomes/metabolism | 2 | 1.0 |
Models, Structural | 2 | 1.0 |
*Protein Structure, Secondary | 2 | 1.0 |
Centrifugation, Density Gradient | 3 | 0.0 |
Ion Transport/genetics | 4 | 40.0 |
Trachea/metabolism | 4 | 22.0 |
Cyclic AMP/*metabolism | 10 | 4.0 |
*Antiporters | 2 | 8.0 |
Cycloheximide/pharmacology | 2 | 0.0 |
Chloride Channels/analysis/*metabolism | 2 | 100.0 |
DNA Primers/genetics | 3 | 0.0 |
Macaca fascicularis | 2 | 0.0 |
Animals, Newborn | 2 | 0.0 |
Gene Targeting | 2 | 0.0 |
Meconium | 2 | 33.0 |
Single-Blind Method | 2 | 0.0 |
Membrane Proteins/metabolism/*physiology | 2 | 6.0 |
*Disease Models, Animal | 2 | 0.0 |
Intracellular Membranes/metabolism | 2 | 1.0 |
Oligodeoxyribonucleotides | 6 | 0.0 |
Spectrometry, Fluorescence | 2 | 0.0 |
Genetic Vectors/*genetics | 3 | 4.0 |
DNA Probes | 3 | 0.0 |
Photochemistry | 2 | 3.0 |
Genes | 2 | 0.0 |
Molecular Probes/genetics | 2 | 2.0 |
Vas Deferens/physiopathology | 2 | 100.0 |
Mice, Nude | 2 | 0.0 |
Sulfates/metabolism | 2 | 3.0 |
Sulfur Radioisotopes | 2 | 2.0 |
Recombinant Proteins/biosynthesis/chemistry/metabolism | 2 | 2.0 |
Iodides/metabolism | 2 | 18.0 |
Genes, Regulator/*genetics | 3 | 7.0 |
Fluorescent Dyes | 3 | 0.0 |
Cystic Fibrosis Transmembrane Conductance Regulator | 133 | 91.0 |
Membrane Proteins/*genetics | 43 | 5.0 |
Methylation | 3 | 0.0 |
Chloride Channels/biosynthesis | 3 | 75.0 |
Membrane Proteins/*biosynthesis/genetics | 2 | 5.0 |
Recombinant Proteins/biosynthesis/drug effects/metabolism | 2 | 100.0 |
Absorption | 2 | 1.0 |
Catalysis | 2 | 0.0 |
Chloride Channels/genetics | 2 | 16.0 |
*Fertilization in Vitro | 2 | 1.0 |
Spermatozoa/*physiology | 2 | 5.0 |
Membrane Proteins/*genetics/metabolism | 5 | 3.0 |
Action Potentials | 2 | 3.0 |
*Cystic Fibrosis | 3 | 100.0 |
*Polymerase Chain Reaction | 3 | 1.0 |
DNA/*genetics | 5 | 1.0 |
Bronchiectasis/*genetics | 2 | 50.0 |
RNA/analysis | 2 | 0.0 |
*RNA Splicing | 7 | 2.0 |
Cystic Fibrosis/genetics/*therapy | 3 | 100.0 |
Membrane Proteins/genetics/physiology | 2 | 8.0 |
Chloride Channels/*genetics | 4 | 7.0 |
Sodium/metabolism/pharmacokinetics | 2 | 100.0 |
Pseudomonas aeruginosa/*pathogenicity | 2 | 20.0 |
Cystic Fibrosis/*genetics/*physiopathology | 2 | 100.0 |
Dystrophin/genetics | 2 | 11.0 |
*Genetic Techniques | 4 | 6.0 |
Oligonucleotide Probes | 2 | 0.0 |
Transcription, Genetic/drug effects | 3 | 0.0 |
Phosphoproteins/chemistry | 2 | 8.0 |
Membrane Proteins/*genetics/*physiology | 2 | 14.0 |
Drug Resistance | 2 | 0.0 |
Membrane Glycoproteins/*genetics | 2 | 0.0 |
P-Glycoprotein | 2 | 4.0 |
Fetus/*metabolism | 2 | 2.0 |
Membrane Proteins/immunology/*metabolism | 2 | 7.0 |
Nucleotides/metabolism | 3 | 8.0 |
Membrane Proteins/*genetics/physiology | 4 | 15.0 |
*Endocytosis | 2 | 1.0 |
Dactinomycin/pharmacology | 2 | 0.0 |
Transferrin/metabolism | 2 | 1.0 |
*Genes, Regulator | 2 | 1.0 |
Antisense Elements (Genetics) | 2 | 3.0 |
Colon/*metabolism | 4 | 7.0 |
Intestine, Small/*metabolism | 2 | 7.0 |
RNA Probes | 2 | 1.0 |
*Chromosomes, Human, Pair 7 | 2 | 0.0 |
Colonic Neoplasms | 5 | 3.0 |
Immunosorbent Techniques | 2 | 0.0 |
Membrane Proteins/chemistry/*genetics | 2 | 3.0 |
DNA/genetics/isolation & purification | 3 | 1.0 |
L Cells (Cell Line) | 3 | 1.0 |
Membrane Proteins/genetics/*physiology | 3 | 5.0 |
Chloride Channels | 13 | 68.0 |
X Chromosome | 2 | 0.0 |
Baculoviridae/genetics | 2 | 1.0 |
Exocytosis/physiology | 2 | 8.0 |
Ion Channels/metabolism | 4 | 15.0 |
Cyclic GMP/pharmacology | 2 | 11.0 |
Membrane Proteins/*physiology | 2 | 1.0 |
Protein Kinases/*metabolism | 2 | 0.0 |
ATP-Binding Cassette Transporters/genetics | 2 | 3.0 |
*ATP-Binding Cassette Transporters | 2 | 1.0 |
Iodides/pharmacology | 2 | 25.0 |
Cystic Fibrosis/*genetics/metabolism/physiopathology | 2 | 100.0 |
Protein Isoforms/genetics/metabolism | 2 | 1.0 |
*Chromosome Deletion | 3 | 0.0 |
RNA, Messenger/*genetics/metabolism | 3 | 4.0 |
Lymphocytes/physiology | 2 | 2.0 |
Cystic Fibrosis/*diagnosis/epidemiology | 2 | 100.0 |
Linkage (Genetics)/genetics | 2 | 0.0 |
Plasmids/genetics | 2 | 0.0 |
Trachea | 2 | 7.0 |
African Continental Ancestry Group/genetics | 2 | 0.0 |
RNA Splicing | 3 | 0.0 |
RNA, Messenger/genetics/isolation & purification | 3 | 5.0 |
Respiratory Mucosa/*physiology | 3 | 42.0 |
Germany | 2 | 0.0 |
Chlorides/chemistry | 2 | 100.0 |
Databases, Genetic | 2 | 2.0 |
United States | 2 | 0.0 |
Serine Proteinase Inhibitors/genetics | 2 | 22.0 |
NF-kappa B/metabolism | 3 | 0.0 |
Quinolizines/*pharmacology | 2 | 100.0 |
Enzyme Activation/physiology | 2 | 1.0 |
Oxidants/pharmacology | 2 | 3.0 |
Trypsin Inhibitor, Kazal Pancreatic/*genetics | 2 | 10.0 |
Nucleic Acid Amplification Techniques/methods | 2 | 16.0 |
*Vesicular Transport Proteins | 2 | 1.0 |
Ion Transport/*genetics | 2 | 50.0 |
Phosphoproteins/metabolism | 2 | 0.0 |
*Neonatal Screening | 2 | 8.0 |
Genetic Predisposition to Disease/epidemiology | 2 | 2.0 |
Ion Transport/*physiology | 2 | 66.0 |
Respiratory Mucosa/drug effects/*physiology | 2 | 33.0 |
Electrophysiology/methods | 2 | 13.0 |